Skip to Content

Acorda Applies To Extend Ampyra Patent Protection

From Associated Press (March 22, 2010)

HAWTHORNE, N.Y. -- Biotechnology company Acorda Therapeutics Inc. said Monday it has applied to extend patent protection for its recently approved multiple sclerosis treatment Ampyra.

The Hawthorne, N.Y., company applied to extend two patents, a move that would allow for up to five additional years of patent protection. The patents expire next year and in 2013. If the extensions are granted, the company will pick one patent to be extended.

Multiple sclerosis affects the brain and nervous system, causing loss of balance, muscle spasms and other movement problems.

The Food and Drug Administration approved Ampyra in January. The agency said then the drug was the first approved to help multiple sclerosis patients walk. The FDA also warned that the drug can cause seizures when given at higher-than-recommended doses, which is anything over 10 milligrams.


Posted: March 2010